All Stories

Candel’s lung cancer survival data light path toward pivotal trial in subpopulation

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially registrational trial.

Mar 27, 2025 - 23:12
 0
Candel’s lung cancer survival data light path toward pivotal trial in subpopulation
Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially registrational trial.
Read More

Tags:

Previous Article

RFK Jr. cuts 4,700 FDA and NIH jobs as HHS eliminates ‘an entire alphabet soup o...

Next Article

Arbutus jettisons 57% of staff, ceases in-house research

Related Posts

Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash

Nanobiotix tweaks J&J licensing deal for phase 3 cancer...

Mar 18, 2025  0

VC firm Kineticos launches biotech to develop fresh approach to antibiotic resistance

VC firm Kineticos launches biotech to develop fresh app...

Feb 24, 2025  0

Q32 Bio sticks with bempikibart, but loses staff and phase 2 complement inhibitor

Q32 Bio sticks with bempikibart, but loses staff and ph...

Feb 11, 2025  0